AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:EGRXEagle Pharmaceuticals Stock Price, Forecast & News

$51.92
-1.49 (-2.79 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$51.91
Now: $51.92
$53.67
50-Day Range
$47.33
MA: $51.67
$55.02
52-Week Range
$33.80
Now: $51.92
$64.94
Volume178,600 shs
Average Volume171,808 shs
Market Capitalization$710.53 million
P/E Ratio305.43
Dividend YieldN/A
Beta1.02
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Read More
Eagle Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.03 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EGRX
CUSIPN/A
Phone201-326-5300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$195.89 million
Cash Flow$1.75 per share
Book Value$13.29 per share

Profitability

Net Income$14.31 million

Miscellaneous

Employees96
Market Cap$710.53 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive EGRX News and Ratings via Email

Sign-up to receive the latest news and ratings for EGRX and its competitors with MarketBeat's FREE daily newsletter.

Eagle Pharmaceuticals (NASDAQ:EGRX) Frequently Asked Questions

How has Eagle Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Eagle Pharmaceuticals' stock was trading at $39.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EGRX shares have increased by 32.9% and is now trading at $51.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Eagle Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Eagle Pharmaceuticals.

When is Eagle Pharmaceuticals' next earnings date?

Eagle Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Eagle Pharmaceuticals.

How were Eagle Pharmaceuticals' earnings last quarter?

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.62. The specialty pharmaceutical company earned $46.02 million during the quarter, compared to analyst estimates of $47.76 million. Eagle Pharmaceuticals had a net margin of 1.29% and a return on equity of 8.11%. View Eagle Pharmaceuticals' earnings history.

What price target have analysts set for EGRX?

2 equities research analysts have issued twelve-month price targets for Eagle Pharmaceuticals' shares. Their forecasts range from $46.00 to $59.00. On average, they expect Eagle Pharmaceuticals' stock price to reach $52.50 in the next twelve months. This suggests a possible upside of 1.1% from the stock's current price. View analysts' price targets for Eagle Pharmaceuticals.

Has Eagle Pharmaceuticals been receiving favorable news coverage?

News articles about EGRX stock have been trending positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 3.0 on InfoTrie's scale. They also gave media headlines about the specialty pharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an effect on the stock's share price in the next several days. View the latest news aboutEagle Pharmaceuticals.

Who are some of Eagle Pharmaceuticals' key competitors?

What other stocks do shareholders of Eagle Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC- (GWPH), Celgene (CELG), Clovis Oncology (CLVS), Horizon Therapeutics (HZNP) and Neurocrine Biosciences (NBIX).

Who are Eagle Pharmaceuticals' key executives?

Eagle Pharmaceuticals' management team includes the following people:
  • Mr. Scott L. Tarriff, CEO & Director (Age 59)
  • Mr. David M. Pernock, Pres & Chief Operating Officer (Age 66)
  • Mr. Pete A. Meyers, Chief Financial Officer (Age 49)
  • Dr. Adrian Hepner, Exec. VP & Chief Medical Officer (Age 58)
  • Mr. Daniel O'Connor, Exec. VP of Biologics & Corp. Devel. (Age 39)

What is Eagle Pharmaceuticals' stock symbol?

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Who are Eagle Pharmaceuticals' major shareholders?

Eagle Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (12.86%), BlackRock Inc. (12.22%), Park West Asset Management LLC (9.02%), State Street Corp (4.57%), Invesco Ltd. (2.37%) and Tang Capital Management LLC (1.87%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View institutional ownership trends for Eagle Pharmaceuticals.

Which major investors are selling Eagle Pharmaceuticals stock?

EGRX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Janus Henderson Group PLC, AJO LP, Morgan Stanley, Morgan Stanley, Squarepoint Ops LLC, and WINTON GROUP Ltd. View insider buying and selling activity for Eagle Pharmaceuticals.

Which major investors are buying Eagle Pharmaceuticals stock?

EGRX stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Schroder Investment Management Group, Matarin Capital Management LLC, Aviva PLC, Acadian Asset Management LLC, Park West Asset Management LLC, Pictet Asset Management Ltd., and Engineers Gate Manager LP. View insider buying and selling activity for Eagle Pharmaceuticals.

How do I buy shares of Eagle Pharmaceuticals?

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Eagle Pharmaceuticals' stock price today?

One share of EGRX stock can currently be purchased for approximately $51.92.

How big of a company is Eagle Pharmaceuticals?

Eagle Pharmaceuticals has a market capitalization of $710.53 million and generates $195.89 million in revenue each year. The specialty pharmaceutical company earns $14.31 million in net income (profit) each year or $1.38 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.

What is Eagle Pharmaceuticals' official website?

The official website for Eagle Pharmaceuticals is www.eagleus.com.

How can I contact Eagle Pharmaceuticals?

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.